<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960437</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR6244</org_study_id>
    <nct_id>NCT03960437</nct_id>
  </id_info>
  <brief_title>The Effect of Etelcalcetide on CKD-MBD</brief_title>
  <acronym>Parsabiv-MBD</acronym>
  <official_title>The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Nickolas, MD MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel
      health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and
      blood-vessels healthier. The study hypotheses are that are that etelcalcetide keeps bones
      strong and lowers the risk of calcium deposits in blood vessels. In Aim 1, the investigators
      will test if 9-months of treatment with etelcalcetide improves bone strength in twenty ESKD
      patients with hyperparathyroidism (HPT) by bone biopsy. In Aim 2, the investigators will test
      if 9-months of treatment with etelcalcetide decreases serum propensity to calcify blood
      vessels. The potential significance of this study is to provide first-time data on the
      ability of etelcalcetide to protect bone and blood-vessel health in patients with ESKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease - mineral and bone disease (CKD-MBD) is a disorder of bone and mineral
      metabolism in patients with CKD. When kidney function is poor, levels of vitamin D, phosphate
      and parathyroid hormone become abnormal and patients are at risk for bone disease and
      fractures (renal osteodystrophy) and the deposition of calcium in blood vessels and muscles.
      CKD-MBD increases the risk of fractures, heart attacks, strokes, and death. Treatment of
      CKD-MBD is focused on lowering levels of parathyroid hormone (PTH) by giving vitamin D and
      lowering levels of phosphorous by giving phosphate binders. In patients with end stage kidney
      disease (ESKD), target levels of PTH recommended by the Kidney Disease Improving Global
      Outcomes (KDIGO) guidelines are in the range of 2-9 times the upper limit of normal (ULN) for
      the PTH assay. In many cases, in patients with long-standing ESKD, the parathyroid gland may
      no longer respond to treatment with vitamin D and phosphate lowering. In these cases,
      treatment with a calcimimetic, a medicine that increases the sensitivity of the parathyroid
      gland to serum levels of calcium, can restore PTH levels to goal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hardness</measure>
    <time_frame>9 months</time_frame>
    <description>Change in hardness will be measured by Ramen nano-indentation and mineralization measured by histomorphometry obtained primary dynamic and secondary structural bone quality outcome values from the pre-treatment baseline to the 6-month endpoint after the 3-month titration period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mineral density (BMD) of the femoral neck by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>9 months</time_frame>
    <description>To test if 9-months of treatment with etelcalcetide improves femoral neck areal BMD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Propensity as measured by T50</measure>
    <time_frame>9 months</time_frame>
    <description>The propensity to calcify soft tissues will be measured by T50 for 9 months of treatment. T50 is a novel serum-based marker that assesses the propensity of calcification in serum. Shorter T50 indicates greater propensity to calcify.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (BMD) of the spine by DXA</measure>
    <time_frame>9 months</time_frame>
    <description>To test if 9-months of treatment with etelcalcetide improves spine BMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (BMD) of total hip by DXA</measure>
    <time_frame>6 months</time_frame>
    <description>To test if 9-months of treatment with etelcalcetide improves total hip BMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation rate</measure>
    <time_frame>9 months</time_frame>
    <description>Following CT scans, specimens will be embedded in methyl methacrylate and sections will be cut with a rotary microtome and either left unstained or stained with McNeal tetracrome or tartrate resistant acid phosphatase for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineralization density</measure>
    <time_frame>9 months</time_frame>
    <description>An integrated Raman/Nanoindentation system will be used, which permits precise measurement of localized bone tissue properties.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Chronic Kidney Disease Mineral and Bone Disorder</condition>
  <condition>Renal Osteodystrophy</condition>
  <condition>Vascular Calcification</condition>
  <condition>Hyperparathyroidism; Secondary, Renal</condition>
  <arm_group>
    <arm_group_label>Study Participant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.</description>
    <arm_group_label>Study Participant</arm_group_label>
    <other_name>Parsabiv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For All Aims:

          1. Patient has provided informed consent.

          2. Patient is 18 years of age or older.

          3. Patient must be receiving maintenance hemodialysis for at least 3 months, with
             adequate hemodialysis with a delivered Kt/V 1.2 or urea reduction ratio (URR) 65%
             within 4 weeks prior to screening laboratory assessments.

          4. Dialysate calcium concentration must be stable for at least 4 weeks prior to screening
             laboratory assessments.

          5. Patient must have severe HPT as defined by two laboratory screening pre-dialysis serum
             PTH values &gt;9-times ULN for the PTH assay, measured on two consecutive monthly lab
             checks prior to entering the study.

          6. The patient has an uncontrolled PTH defined by KDIGO as a PTH greater than 9 times the
             upper limit of normal of the assay (720 pg/mL for Rogosin):

             AND one of the following:

               -  The patient has never been on cinacalcet OR,

               -  The patient received daily cinacalcet for less than 3 months and has been off
                  cinacalcet for at least 3 months prior to enrollment OR ,

               -  The patient received daily cinacalcet for more than 3 months and has been off
                  cinacalcet for at least 6 months prior to enrollment OR,

               -  The patient received a modified dose of three times weekly cinacalcet and has
                  been off cinacalcet for at least one month prior to enrollment.

          7. Scheduled to receive etelcalcetide for the treatment of HPT per standard of care.

          8. If receiving vitamin D sterols, patient must have had no more than a maximum dose
             change of 50% within the 4 weeks prior to screening laboratory assessments, remain
             stable through randomization, and be expected to maintain stable doses for the
             duration of the study, except for adjustments allowed per protocol*.

          9. Patient must have one screening pre-dialysis serum Ca laboratory value at least at the
             lower limit of normal for the assay measured within 4 weeks prior to entering the
             study.

         10. A patient receiving calcium supplements must have had no more than a maximum dose
             change of 50% within 2 weeks prior to screening laboratory assessments and remain
             stable throughout the study, except for adjustments allowed per protocol*.

         11. A patient receiving phosphate binders must have had no more than a maximum dose change
             of 50% within the 2 weeks prior to screening laboratory assessments, remain stable
             through, and be expected to maintain stable dose for the duration of the study, except
             for adjustments allowed per protocol*.

         12. The treating physician considers the etelcalcetide dose and timing points described in
             this protocol as acceptable/optimal for their patient.

         13. Female patients must be willing to use highly effective contraception during the study
             and for 3 months after the last dose of etelcalcetide (unless postmenopausal or
             surgically sterilized).

        For Aim 1:

        1. Total alkaline phosphatase â‰¥ the upper tertile of the reference range for the assay

        Exclusion Criteria:

        For All Aims:

          1. Currently receiving treatment in an investigational device or drug study, or less than
             30 days since ending treatment on an investigational device or drug study(s).

          2. Currently receiving investigational procedures while participating in this study.

          3. Patient with controlled PTH as defined by KDIGO as a PTH of 2 to 9 times the upper
             limit of normal of the assay.

          4. Patients has received a bisphosphonate, denosumab or teriparatide during the 12 months
             prior to screening.

          5. Anticipated or scheduled parathyroidectomy during the study period.

          6. Patient has received a parathyroidectomy within 6 months prior to dosing.

          7. Scheduled kidney transplant during the study period or anticipated living donor
             evaluation within three months of recruitment

          8. Patient has an unstable medical condition based on medical history, physical
             examination, and routine laboratory tests, or is otherwise unstable in the judgment of
             the Investigator.

          9. Bilateral lower extremity amputations or non-ambulatory

         10. Metabolic bone diseases not related to the kidney (i.e., Pagets, Osteogenesis
             Imprefecta)

         11. Untreated hyperthyroidism or hypoparathyroidism

         12. Malignancy within the last 5 years (except non-melanoma skin cancers or cervical
             carcinoma in situ).

         13. Patient is pregnant or nursing.

         14. Patient likely to not be available to complete all protocol-required study visits or
             procedures, and/or to comply with all required study procedures to the best of the
             patient and Investigator's knowledge.

         15. Weight &gt;300 pounds

        For Aim 1 (Bone biopsy):

        1. Allergy to tetracycline or demeclocycline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Nickolas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas L Nickolas, MD,MS</last_name>
    <phone>212-305-9847</phone>
    <email>tln2001@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Sung</last_name>
    <email>jcs2269@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas L Nickolas, MD MS</last_name>
      <phone>212-305-9847</phone>
      <email>tln2001@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Thomas Nickolas, MD MS</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Bone disease</keyword>
  <keyword>Etelcalcetide</keyword>
  <keyword>Parsabiv</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

